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Sununary. We previously reported that mortality due to
ischaemic heart disease was lower in haemophilia patients
than in the general male population. To support the hypothe-
sis that this could be attributed to a protective effect of the
clotting defect in haemophilia and not to differences in
cardiovascular risk factors, we performed a second study. We
examined 95 haemophilia patients for the presence of major
risk factors for ischaemic heart disease and compared their
risk factor profile with the data of epidemiologic surveys of the
general Dutch population.
Haemophilia patients had on average higher blood pres-
sures than the comparison population, were more often
hypertensive and used antihypertensive drugs twice äs often.
The mean serum cholesterol level of the patients was
markedly lower than in the comparison population (4-8
versus 5-6 mmol/1, 95% confidence interval of the difference:
0-5-Mmmol/l).
The risk factors were weighted into one theoretical risk
raüo for ischaemic heart disease by application of logistic
regression coefficients. The theoretical risk ratio based on the
risk factor profile was 0-78. This risk ratio can only explain a
moderate reduction in the incidence of ischaemic heart
disease, much smaller than the mortality ratio of 0-20 we
reported previously. Therefore these data support the hypo-
thesis of a direct protective effect of haemophilia on the
development of ischaemic heart disease.
Recently we reported the results of a follow-up study on
mortality in a cohort of 717 patients with haemophilia
(Rosendaal et al, 1989). Among a total of 43 deaths, the
mortality from ischaemic heart disease was markedly
reduced in comparison with the general male population: a
mortality ratio of only 0-20, after adjustment for age.
The low mortality of ischaemic heart disease was striking:
first, because overall mortality in the cohort was twice äs
high äs expected; second, because it occurred in the face of a
high prevalence of hypertension, äs judged by the frequent
use of antihypertensive drugs by haemophilia patients
(Rosendaal et al, 1989). Although this has not been docu-
mented, many haematologists feel that haemophilia predis-
poses to hypertension. A high occurrence of renal disease
among haemophiliacs has been reported (Lazerson, 1976;
Prentice et al, 1971), which was reflected in our previous
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study in a higher than expected mortality from renal
insufflciency (Rosendaal et al, 1989).
One is tempted to attribute the low mortality ratio from
ischaemic heart disease of 0-20 to the clotting deficiency.
This would be justified under two assumptions: first, that the
shortfall was not caused by so-called competing risks. A low
mortality ratio of ischaemic heart disease could result if other
death causes with excess mortality, e.g. stroke, renal failure
and cancer, had removed exactly those patients who would
otherwise later have died from ischaemic heart disease. Such
mechanisms are unlikely, and even if present would also
have an effect in the general population with which the
mortality was compared, so that this consideration would
account for only a very small fraction of the difference in
mortality from ischaemic heart disease.
The second assumption one needs to make in Order to
attribute the low mortality of ischaemic heart disease to the
clotting deficiency, is that all other factors relevant to the risk
of myocardial infarction were equal among patients and the
general population. The present study was conducted to
verify this assumption. We examined the classical risk factors
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for ischaemic heart disease, smoking, blood pressure and
cholesterol, in haemophilia patients attending the outpatient
clinics of two haemophilia centres and compared these to
data from two large epidemiologic surveys in the Dutch
general population. For each factor the observed risk factor
level was compared with the expected risk factor level derived
from these surveys. Subsequently, we combined the factors
into one overall risk ratio, the 'theoretical risk ratio', based
solely on the risk factor profile. This was done by application
of logistic coefflcients äs determined in a study on myocardial
infarction in Dutch postal employees (Vandenbroucke &
Matroos, 1981).
In the previous study on mortality in haemophilia (Rosen-
daal et al, 1989), cancer deaths were conspicuous: 15 deaths
from neoplasm occurred while only six were expected. Since
six of these were neoplasms of the lung, the question of a
higher smoking frequency among haemophilia patients was
raised.
METHODS
All 128 haemophilia patients of the haemophilia centres in
Rotterdam and Leiden were invited to participate in this
study. For the Leiden centre this also included pediatric
patients, while the Rotterdam clinic included only adults. The
patients were mailed a small questionnaire that they
returned on the day of the examination.
The examination took place in the outpatient clinics of the
two centres. The patients were interviewed with regard to
smoking habits, ehest pain, history of cardiac disease, and use
of medical drugs. Blood pressure was measured by one of us
(F.R.R.) with a random-zero-sphygmanometer, after the
patient had had a minimum of 15 min of rest. Diastolic
pressure was noted äs Korotkov's phase 5, which conforms to
American Heart Association recommendations (Kirkendall
et al, 1981). Blood pressure was taken with the patient in a
sitting Position, before venopuncture and electrocardiogram
(ECG). Hypertension was deflned according to the Standards
of the World Health Organization, at a systolic pressure of
160 mmHg or higher, or a diastolic pressure of 95 mmHg or
higher (WHO, 1978). The ECGs were judged by a cardiologist
(G.vH.) who was unaware of the patient's medical history.
Total cholesterol concentrations were determined by an
enzymatic assay (Boehringer Mannheim, F.R.G.), while high-
density lipoproteins (HOL) were measured after sodium
phosphate tungstate precipitation äs described by Lopes-
Virella ei al (1977). In this way both the measurements of
blood pressure, with the random-zero-sphygmanometer, and
cholesterol were performed in a way identical to that of the
population survey to which the results were compared
(EPOZ, see below). In this population survey cholesterol levels
were also determined by an enzymatic method and in this äs
well äs in our study the World Health Organization Standard
of the regional lipid reference centre in Prague was used
(Valkenburg et al, 1980). Serum creatinine concentrations
were measured äs a crude index of renal function in the
Standard fashion. As a measure of relative body weight the
Quetelet index was determined (weight (kg)/length (m)2).
For comparison we used data obtained between 1975 and
1978 in the population based EPOZ study ('Epidemiologie
Prevention Study Zoetermeer'), which was carried out in the
Dutch town of Zoetermeer, between Leiden and Rotterdam.
This study, in which 10 532 persons participated, was aimed
at obtaining prevalence flgures for major chronic diseases
and their risk factors. From this study data were available of
5075 men grouped in 5-year age intervals on cholesterol
level, blood pressure, Quetelet index and use of antihyper-
tensive medication. As has been described elsewhere, the
results of this survey are considered to be representative for
the Dutch population (Valkenburg et al, 1980; Hofman &
Valkenburg, 1980, 1983).For comparison of smoking habits
between the patients and the general population, Informa-
tion was made available from a large (9705 men) national
survey on smoking that took place in 1988, and earlier
surveys from 1972 onwards (Stichting Volksgezondheid en
roken, 1988; Central Bureau of Statistics, 1986). We made
no distinction between cigarette smoking and other types of
tobacco smoking.
Adjustment for age differences between patients and the
reference population was performed by standardization with
the age distribution of the patients äs weights. This led to the
calculation of an expected risk factor profile, i.e. that one
would encounter in a group of men from the general
population with the same age distribution äs the patients.
The Standard error of the standardized values was obtained
by calculation of a weighted average of the Standard errors in
each 5-year age group with the squared size of the age groups
in the patient population äs weights. The Standard error of
each risk factor in the patients and the Standard error of the
standardized expected risk factor value were pooled to obtain
a 95% confldence interval of the risk factor difference.
We then calculated the odds ratio for ischaemic heart
disease of patients in comparison with the reference popula-
tion combining the factors smoking, cholesterol, systolic
blood pressure and Quetelet-index. This odds ratio estimates
the theoretical risk ratio for myocardial infarction, given the
levels of the risk factors we studied. We weighted the values of
these factors by application of the coefflcients of a logistic
regression model of a study on flrst myocardial infarction of
Dutch postal employees (Vandenbroucke & Matroos, 1981).
The coefficients reported from this study for systolic blood
pressure (0-0155 mmHg), cholesterol (0-011 mg/dl, i.e.
0-4231 mmol/1) and Quetelet-index (0-0052 kg/m2) were
almost identical to those found in the Framingham Heart
study (Truett et al, 1967). The Dutch study discriminated
between smokers and non-smokers (coefflcient 0-8510),
while in the report from the Framingham study coefficients
were given for medium and heavy smoking.
The study on Dutch postal employees from which the
logistic coefficients were derived, included only individuals of
40 years and older, i.e. on average older than the haemophi-
lia patients and the EPOZ reference population. One might
question the use of logistic coefficients derived from an older
group, even when adjustment has been performed for the age
difference between the haemophilia patients and the EPOZ
reference population. Therefore, we provide a separate
analysis limited to the patients aged 40 years and older.
In the logistic model the logarithm of the odds on disease
Table I. Observed and expected risk factor profile
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Table II. Theoretical odds risk ratio of myocardial disease
Observed
Factor
Systolic pressure
(mmHg)
Diastolic pressure
(mmHg)
Total cholesterol
(mmol/l)
Smokers (%)
Quetelet index (kg/m2)
Mean
133
82
4-8
44
22-8
CI95
129-137
80-85
4-5-5-0
34-54
22-0-23-7
Expected
Mean
129
77
5-6
41
23-2
CI95
129-130
76-77
5-5-5-6
40-42
23-2-23-3
Under Observed' the risk factor profile of the patients is shown,
with a 95% confidence interval (CI95) of the mean of each factor.
Under 'expected' the risk factor profile of the comparison population
is given, standardized for age differences. For the patients all factors
refer to 95 patients, except for the figures on smoking which refer to
87 patients aged 15 years and older. The expected values refer to
4974 men for blood pressure, 4913 men for cholesterol. 9705 men
(aged 15 years and older) for smoking and 4929 men for Quetelet
indices.
is written äs a linear function of the factors, ln(odds) =
α + Έ,(βιΧι), in which x, are the values of the risk factors and ß,
the corresponding coefficients. The odds ratio on myocardial
infarction for patients (P) in comparison with the reference
population (R) becomes the antilog of ΣβΑχ,* — x,.t)·
In this analysis the coefficients are applied to the standard-
ized average risk factor values in patients and reference
population. Two populations with the same average value,
however, could have very different risks if the distribution of
risk factor levels differed widely, because of the exponential
relation of risk and risk factor. For instance, if in population A
all individuals had a cholesterol level of 5-0 mmol/l and in
population B half of the individuals had levels of 2-0 mmol/l
and the other half of 8-0 mmol/l, average levels would be
equal. Nevertheless, the risk in population B would be almost
double to that of population A. We compared the distribution
of the risk factors in the patients and the reference population
by the variance ratio (patients over reference population,
overall variance), which was l -04 for systolic blood pressure,
1-32 for cholesterol levels, and 0-92 for Quetelet index; none
of these, äs tested by the F-distribution differed signiflcantly
(P-value<0-05) from a variance ratio of 1-0.
RESULTS
Ninety-five out of 128 patients (74%), 48 in Leiden and 47 in
Rotterdam, agreed to participate in the study. Eighty-seven
(92%) of the 95 patients had haemophilia A, eight had
haemophilia B. Thirty-three (35%) had severe haemophilia
(less than 1% clotting factor activity), 15 (16%) had modera-
tely severe haemophilia (1-5% activity) and 47 (49%) had a
mild form (more than 5% activity). Their age ranged from 7
to 76 years (mean age 38 years). This age distribution did not
differ much from that of the EPOZ reference population, in
which the mean age was 32 years.
Factor (i)
Systolic pressure (mmHg)
Diastolic pressure (mmHg)
Total cholesterol (mmol/l)
Smokers (%)
Quetelet index (kg/m2)
Theoretical risk odds ratio
Difference
3-7
5-8
-0-8
3
-0-4
= e *«*"-*·
CI95
-0-3-7-7
3-6-8-0
-1-1 — 0-5
-7-12
-1-3-0-4
.R)
 = e -Ü2554
Coefficient
ß,
0-0155
0-4231
0-00851
0-0052
= 0-78
The difference is the observed risk factor level of the patients (P)
minus the expected level of the reference population (R). The 95%
confidence interval of the difference (CI95) is based on the pooled
Standard error of the patient group's Standard error and the error of
the standardized expected factor level which, since the latter
Standard errors were very small, is almost identical to the patient
factor Standard errors alone.
Table I shows the observed risk factor values in the patients
and the expected risk factor values from the comparison
population. Both the systolic and diastolic blood pressures
were higher among the patients than in the comparison
population. Total cholesterol levels were lower, while the
Quetelet indices and the percentage of smokers were about
equal. The application of the coefflcients of the logistic model
for these four factors led to a theoretical odds risk ratio for
ischaemic heart disease of patients over comparison popula-
tion of 0-78 (Table Π). This means that, based solely on the
risk factor profile, the patients' odds for myocardial infarction
were 22% lower than in the comparison population. When
the analysis was limited to the 42 patients aged 40 years and
older, and expected risk factor levels were calculated for this
group. application of the logistic coefficients resulted in a very
similar odds ratio of 0-80.
In addition to the higher mean blood pressure levels among
the patients, the use of antihypertensive drugs was more
common among the patients. Among the 5075 men of the
EPOZ reference population 4-1% used antihypertensive
drugs, while ll-6%(ll/95)of the patients were treated with
these drugs. After age adjustment (by weightmg to the age
distribution of the patients) the observed frequency of use
of antihypertensive agents was still 2-3 times äs high äs
the expected frequency. If we consider hypertensive those
individuals who either have blood pressures exceeding
160 mmHg systolic or 95 mmHg diastolic, or receive anti-
hypertensive drug treatment, patients were 1-9 times äs often
hypertensive äs the comparison population (after age-stan-
dardization). To verify whether patients were treated with
antihypertensive drugs at lower blood pressures than the
reference population, we compared the individuals who were
not treated with antihypertensive drugs. Among these, the
patients were l · 5 times äs often hypertensive äs the reference
population (systolic pressure over 160 mmHg or diastolic
over 95 mmHg). Taken together, these Undings Support the
clinical Impression that hypertension is common among
haemophilia patients. We could not observe any relation
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Fig 1. Percentage smokers from 1972 to 1988. Patients: +;
Population: *. The percentage of smokers of the patients is adjusted
for age by standardization. The data for 1972, 1975, 1979, 1982
and 1984 compare individuals from 13 years and older. They refer to
surveys of the Dutch population numbering 12 191, 4607, 4454,
3398 and 3324 males, respectively (Central Bureau of Statistics,
1986). The data of 1988 were compared to the NIPO-survey,
numbering 9705 males (Stichting Volksgezondheid en Roken, in The
Hague, unpublished observation).
between severity of haemophilia and hypertension. The
prevalence of hypertension among the patients was strongly
associated with age: up to 24 years of age none were
hypertensive, between 25 and 49 years of age 7/45 were
hypertensive (16%) and among those aged 50 or more 15/26
(58%).
Since a high occurrence of renal disease among haemo-
philia patients has been reported (Lazerson, 1976; Prentice
et al, 1971) äs well äs an increased mortality due to renal
insufficiency (Rosendaal et al, 1989), we measured plasma
creatinine levels äs a crude index of renal function to see if
this was related to the occurrence of hypertension. After
adjusting for age by logistic regression on hypertension,
defined äs either hypertensive blood pressure or use of
anöhypertensives, creatinine levels did not prove to be
associated with the occurrence of hypertension (quartiles of
creatinine levels. 0=0-05, OR=1-05).
44% of the patients (38/87 patients aged 15 years and
older) were current smokers, äs compared to 41% in the
comparison population.
Since Information on beginning and giving up smoking
was available, we could compare the percentage of smokers
within the patient group from 1972 to the present with the
Dutch male population. From Fig l there appears to be no
difference between the smoking habits in both groups.
The haemophilia patients had markedly lower levels of
serum cholesterol than the comparison population. The
mean serum cholesterol concentration was 3 · 8 mmol/1 in the
patients younger than 25 years, 4-8 mmol/1 in those aged
25-49, 5-2 mmol/1 for the ages 50-64 and 6-2 mmol/1 in the
patients aged 65 and older. The patients with severe
haemophilia had on average the lowest cholesterol levels.
For severe haemophilia the mean cholesterol level was
4-4 mmol/1, for moderately severe haemophilia it was
4-7 mmol/1 and for mild haemophilia 5-0 mmol/1. The
concentration of HOL cholesterol was 1-0 mmol/1 on aver-
age, and did not differ by age or severity of haemophilia.
When we performed linear regression with age and severity
äs independent variables on total cholesterol concentration,
patients with more severe forms of haemophilia still had the
lowest cholesterol levels, although the 95% confidence
interval of the regression coefficient included zero.
No data on the Dutch population were available to
compare the HOL cholesterol. The mean level of l -0 mmol/1 is
lower than that reported in studies from the United States. In
one study on 2568 men an average HDL cholesterol level of
1-4 mmol/1 was reported (Williams et al, 1979), while in the
Framingham study the median HDL cholesterol level for
1189 men was 1-14 mmol/1 (Wilson et al, 1988). This latter
figure was deduced from the ränge of the third quintile, the
mean value will in fact be even higher because of the right
skewed distribution.
Another approach to the question of a protective effect of
haemophilia against the development of myocardial infarc-
tion, was to look for evidence of ischaemic heart disease
among these 95 patients. This was examined both by an
interview for anginal complaints and a resting electrocardio-
gram. None of the patients had a history of myocardial
infarction. One 44-year-old patient with mild haemophilia A
reported typical exercise related angina. None of the electro-
cardiograms provided evidence for old myocardial infarc-
tions, although one was considered suspect. This 61-year-old
patient with mild haemophilia A did not report any history of
ehest discomfort. Since no Information on the prevalence of
ischaemic abnormalities was available for the general popu-
lation, these data could not be compared to an expected
figure.
DISCUSSION
The theoretical mortality ratio for myocardial infarction of
0-78, based solely on the risk factor profile, cannot explain
the observed mortality ratio of 0-20 (Rosendaal et al, 1989).
Therefore we conclude that haemophilia may offer direct
protection against myocardial infarction.
The risk odds ratio of 0-78, which predicts a theoretical
22% lowering of the risk of myocardial infarctions because of
the risk factor profile, might even be closer to l, since many
patients received antihypertensive treatment. Clinical trials
have shown that pharmaceutical treatment of hypertension
is far more effective in preventing peripheral organ damage
than coronary artery disease (Veterans Administration Co-
operative Study Group on Antihypertensive Agents, 1970;
Strate et al, 1986). It seems likely that treatment does not
reduce the risk of myocardial infarction to the figure of
normotensive individuals, even when normal blood pres-
sures are reached. This implies that the risk factor profile of
the patients would differ even less from that of the compari-
son population.
The comparability of the risk factor proflles of the patients
and the population of the epidemiologic surveys has to be
addressed. Since the patients were living in the geographical
area where the EPOZ study was performed, we have little
doubt that this was the right reference group for comparison.
The flgures on smoking were compared to a very large
survey performed in the year preceding our study and
therefore the comparison may be considered fair. One might
question, however, whether any major changes occurred in
the general population or in laboratory methods during the
10-year interval between the EPOZ study and ours. Health
education may have lowered cholesterol levels because of
dietary measures. It is unlikely, however, that this would
account for a 0-8 mmol/1 difference. In both studies,
cholesterol deterniinations were standardized to the same
reference centre, and therefore differences between laborator-
ies or secular changes in laboratory methods cannot explain
the difference.
Blood pressures are also not very likely to have changed
with time, while the consumption of antihypertensive drugs
in The Netherlands has remained fairly constant (Institute for
Medical Statisücs, 1988). The overall mortality of ischaemic
heart disease in the Dutch male population has decreased by
15% since the 1970s [from 214 in 1975 to 182 in 1984, per
million, standardized to the population of 1960 (Central
Bureau of Statistics, 1986)]. This decrease coincided with a
reduction in the number of smokers from 63% in 1975 to
49% in 1984 (Central Bureau of Statistics, 1986). These
figures indicate that no major changes in the risk factors
other than smoking have occurred in the general population
between the time of the epidemiologic surveys and our study
that might have rendered the comparison unjustified.
Our Undings confinn the Impression that haemophilia
patients are often hypertensive. It could be argued that the
close medical care received by haemophilia patients makes it
more likely that hypertension is detected and subsequently
treated. This, however, appeared not to be an explanation for
the high frequency of hypertension among haemophilia
patients, since the mean blood pressures were also higher
than expected in the patients not treated for hypertension.
Moreover, even though antihypertensive treatment was
more than twice äs common äs in the comparison popula-
tion, the overall mean blood pressures were still higher than
expected.
An unexpected Unding in this study was the marked
difference in cholesterol levels between the patients and the
comparison group. It seems plausible that the low cholesterol
levels we observed were associated either with the clotting
defect or with its treatment, since they were lowest in the
patients with severe haemophilia. Patients with haemophilia
are during their lifetime heavily exposed to foreign proteins,
which affect the immune System äs well äs liver function,
because of viral infections. These alterations caused by
treatment with preparations from human plasma might offer
an explanation for the low cholesterol levels. Low cholesterol
concentrations have been associated with an increased
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cancer incidence in several large studies (Rose et al, 1974;
Morris et al, 1983; International Collaborative Group, 1982).
In our follow-up study on mortality we also observed a high
cancer mortality in haemophilia patients (Rosendaal et al,
1989). It is a matter of some debate whether the observations
associating low cholesterol levels with an increased cancer
risk represent a true effect of low cholesterol (McMichael et al,
1984). Recent reports show that the effect can only be
observed in the flrst few years of follow-up, which makes it
most likely that the association is caused by preclinical
cancers lowering cholesterol (Sherwin ei al, 198 7; Knekt etal,
1988).
A large proportion of the excess cancer deaths we reported
in our previous paper was caused by cancers of the lung
(Rosendaal ei al, 1989). One of the possible explanations
offered was a preponderance of smokers among haemophilia
patients. Other hypotheses were an effect inherent to the
clotting deficiency itself or its treatment and in particular the
immune alterations caused by replacement therapy (Brettler
et al, 1986; Madhok et al, 1986). When current smoking and
past smoking were taken together, no preponderance of
smokers among haemophilia patients emerged.
Myocardial infarction is the result of many years of
atherosclerotic coronary disease followed by coronary
thrombosis (DeWood et al, 1980). A protective effect of low
clotting factor levels has been shown for fibrinogen (Wilhelm-
senetal, 1984; Kännel et o], 1987) and factor VÜ(Meade et al,
1986). It can be deduced from the report of the Northwick
Park study (Meade et al, 1986) that individuals in the general
population in the highest tertile of factor VHI levels had a 40%
higher risk of myocardial infarction than those in the lowest
tertile. This association was reported to be non-significant
(P=0 · 2). It has to be borne in mind, however, that the factor
VHI levels are far lower in haemophilia patients than in the
non-haemophilic population of the Northwick Park study.
Taken together these data suggest that also in the non-
haemophilic population low factor VIII levels have a protec-
tive effect. It remains unresolved whether the protective effect
only applies to the final thromboüc event, or also to the
atherosclerotic process itself. It may well be possible that
clotting factor activity is a necessary or promoting factor in
the formation of atherosclerotic plaques. The Unding of a
protective effect of a clotting deficiency is in accordance with
the reports of a beneficial effect of oral anticoagulants in the
prevenüon of recurrent myocardial infarction (Sixty-plus
Reinfarction Study Research Group, 1980; Smith et al,
1989), although this effect has been the subject of an
interminable and never settled dispute since it was first
postulated.
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